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Monoclonal antibodies b12 and 4E10 are broadly neutralizing
against a variety of strains of the human immunodeficiency virus
type 1 (HIV-1). The epitope for b12 maps to the CD4-binding site in
the gp120 subunit of HIV-1’s trimeric gp120-gp41 envelope spike,
whereas 4E10 recognizes the membrane-proximal external region
(MPER) of gp41. Here, we constructed and compared a series of
architectures for the b12 and 4E10 combining sites that differed in
size, valency, and flexibility. In a comparative analysis of the ability
of the b12 and 4E10 constructs to neutralize a panel of clade BHIV-1
strains, we observed that the ability of bivalent constructs to
cross-link envelope spikes on the virion surface made a greater
contribution to neutralization by b12 than by 4E10. Increased
distance and flexibility between antibody combining sites corre-
lated with enhanced neutralization for both antibodies, suggest-
ing restricted mobility for the trimeric spikes embedded in the
virion surface. The size of a construct did not appear to be
correlated with neutralization potency for b12, but larger 4E10
constructs exhibited a steric occlusion effect, whichwe interpret as
evidence for restricted access to its gp41 epitope. The combination
of limited avidity and steric occlusion suggests a mechanism for
evading neutralization by antibodies that target epitopes in the
highly conserved MPER of gp41.
HIV type 1 (HIV-1) is an enveloped virus that presents severechallenges to eliciting effective antibody-mediated immune
responses because it employs multiple strategies to evade anti-
bodies. The virus rapidly mutates to change residues on its
surface (1), conceals other potential antibody epitopes with
carbohydrates (2), hides conserved regions at interfaces by
oligomerization, and prevents access to conserved regions by
conformational masking and steric occlusion (2–5). Despite
these escape mechanisms, a limited number of broadly neutral-
izing antibodies have been isolated from HIV-1-infected indi-
viduals over the past few decades (reviewed in ref. 6). They target
well-defined epitopes on both subunits of the HIV-1 envelope
spike, a trimeric complex composed of 3 copies of 2 nonco-
valently associated glycoproteins, gp120 and gp41. One such
antibody called b12 binds to an epitope that overlaps the host
receptor (CD4)-binding site on gp120 (7, 8), and another called
4E10 binds to an epitope in the highly conserved membrane
proximal external region (MPER) of gp41 (9–12). Both anti-
bodies were shown to be broadly neutralizing across a diverse
panel of HIV-1 strains, although 4E10 exceeded b12 in the
breadth of its reactivity (13).
The neutralization potency of an antibody against a virus can
be improved by orders of magnitude through the effects of
avidity (14–18). The term avidity in the context of antibodies
refers to their ability to simultaneously bind 2 physically linked
antigens (e.g., 2 spikes on the surface of the same virus) by using
the 2 identical combining sites located at the tips of their Fab
(antigen-binding fragment) arms (19) (Fig. 1). In order for
avidity to occur, the antigen sites must be present at sufficient
density such that once the first Fab has bound, the second Fab
can bind its partner before the first Fab dissociates. The number
of spikes on HIV-1 is 15 per virion (20–23), whereas 450
spikes per virion have been observed on the similarly sized
influenza typeA virus (24). The extent to which the relatively low
density of HIV-1 envelope spikes might impact the avidity of
anti-HIV-1 antibodies is not yet understood.
Our objective in the present study was to ask how the
difference between monovalence and bivalence coupled with
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Fig. 1. Structures of antibody constructs. Space-filling models are presented
above a description of the domain organization for each construct (VL, vari-
able light; VH, variable heavy; (G4S), Gly-Ser linker; H6, 6-His tag). Models
were constructed by using coordinates for the heavy (blue) and light (yellow)
chains of Fab 4E10 and its peptide epitope (red) (PDB ID code 1TZG) (34). For
the diabody model, 2 4E10 VH–VL pairs were aligned to the structure of
diabody L5MK16 (PDB ID code 1LMK) (30). For the IgG model, 2 4E10 Fabs were
used to replace the b12 Fabs in the structure of intact IgG1 b12 (PDB ID code
1HZH) (55). Solid lines indicate approximate dimensions for the scFv, diabody,
and Fab. Dotted lines indicate approximate maximal distances between com-
bining sites for the scBvFv and IgG. Curved black arrows indicate axes of
rotation.
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differences in size and flexibility contribute to the neutralization
mechanisms of b12 and 4E10. Using an in vitro neutralization
assay, we compared the potencies of b12 and 4E10 constructs
against a panel of clade B HIV-1 strains. Our results demon-
strated that avidity enhanced neutralization by IgG b12 but only
weakly enhanced neutralization by IgG 4E10, and the contribu-
tion of avidity to b12-mediated neutralization was usually most
apparent for strains that were relatively insensitive to monova-
lent b12 reagents. Moreover, we observed that flexibility and
distance between the antigen-binding sites of bivalent forms of
both antibodies enhanced neutralization potency and that in-
creased size limited neutralization by 4E10 but not b12. The
implications of these results on antibody escape by HIV-1 and
vaccine design are discussed.
Results
Neutralizing Antibody Fragments Are Stable and Exhibit Correct
Oligomerization. To systematically compare affinities and neu-
tralization potencies as a function of size, number, and arrange-
ment of combining sites, we produced monovalent and bivalent
forms of b12 and 4E10. As monovalent forms, we produced the
combining sites as Fabs and as scFvs (single chain variable
fragments), in which a 15-residue flexible Gly-Ser linker was
used to link the variable heavy and variable light (VH and VL)
domains in a single polypeptide chain (25, 26) (Fig. 1). We made
3 different bivalent forms of each antibody: the traditional IgG,
a single chain bivalent Fv (scBvFv), and a diabody (Fig. 1). The
scBvFv was constructed by joining 2 scFv fragments with a third
Gly-Ser linker, thereby forming a single polypeptide chain with
2 antibody combining sites of identical specificities (27). In this
form of bivalent reagent, the 2 combining sites are expected to
be free to rotate with respect to each other. The diabody form
was constructed by expressing a scFv with a short linking region
(28), which promoted pairing between a VH domain and a VL
domain on separate polypeptides to form a 3D domain-swapped
dimer (29). Relative to scBvFvs, diabodies are expected to be
more rigid, with 2 combining sites facing in approximately
opposite directions (30). In total, we produced the Fab and IgG
forms of b12 and 4E10 as well as 6 different scFv-based
constructs (scFv b12, scBvFv b12, diabody b12, scFv 4E10,
scBvFv 4E10, and diabody 4E10).
The scFv-based proteins were purified by Ni-NTA and size-
exclusion chromatography and analyzed by SDS/PAGE (Fig. 2 A
and B). To verify that each of the proteins exhibited the expected
oligomeric state, molecular weights were determined by in-line
multiangle static light scattering coupled with size-exclusion
chromatography (Fig. 2C). The results were consistent with the
theoretical molecular weights of the scBvFvs and diabodies,
which are approximately twice the molecular weight of a scFv,
demonstrating that the scFvs and scBvFvs were monomeric and
the diabodies were dimeric.
Bivalent b12 and 4E10 Reagents Can Bind with Avidity. The antigen
binding activities of the b12 and 4E10 proteins were evaluated by
using a surface plasmon resonance-based binding assay. For
these experiments, we injected b12 reagents over immobilized
monomeric gp120 and 4E10 reagents over immobilized gp41.
During neutralization, antibodies bind to a gp120-gp41 envelope
spike trimer on the surface of the virus rather than to the
separated chains that can be expressed and purified for binding
assays. Thus, an affinity derived from this binding assay cannot
be used to deduce the affinity of an antibody for its epitope on
the surface of a virus. Instead, the binding assays were used to
verify that each of the reagents bound its antigen and to
determine whether the bivalent constructs could cross-link im-
mobilized antigens on the sensor surface, which would be
revealed by avidity effects resulting in higher apparent affinities
relative to the counterpart monovalent constructs.
Fig. 2. Biophysical characterization of the antibody constructs. (A) Reduced SDS/PAGE. (B) Gel filtration profiles. (C) Molecular weight determinations and
binding experiments. Observed results from static light scattering experiments (Obs) are presented beside molecular weights calculated from the relevant
sequence (Calc) in column 2 (n.d., not done). Kinetic and equilibrium constants are presented in columns 3–5.
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All of the b12 and 4E10 reagents exhibited high antigen binding
affinities with equilibrium dissociation constants (KDs) in the
nanomolar or picomolar range [Fig. 2C and supporting information
(SI) Fig. S1]. The KDs for the monovalent b12 reagents (scFv and
Fab) were in close agreement (2.2 nMand 1.2 nM, respectively). All
of the bivalent b12 reagents bound to gp120 with higher apparent
affinities: 80 pM for IgG b12, 250 pM for scBvFv b12, and 190 pM
for diabody b12 (Fig. 2C), demonstrating that each of the bivalent
constructs contained 2 functional antigen-binding sites that could
cross-link adjacent immobilized antigens. The larger distance be-
tween the binding sites in an IgG compared with the binding sites
in a scBvFv or diabody (Fig. 1) would be expected to lead to
increased cross-linking efficiency, rationalizing the higher apparent
affinity of the IgG compared with those of the scBvFv and diabody.
The results obtained for the 4E10 reagents also showed an affinity
enhancement for the bivalent reagents over the monovalent re-
agents: The scFv and Fab bound to gp41 with KDs of 35 nM and 32
nM, respectively, consistent with the 20 nM KD reported for Fab
4E10 binding to a gp41-derived peptide (31), and the IgG, scBvFv,
and diabody bound with apparent KDs of 5.7 pM, 160 pM, and 310
pM, respectively (Fig. 2C).
Ability to Cross-Link Epitopes on a Virus Contributes to Neutralization
by b12. Pseudovirus neutralization assays were performed for
antibody constructs against a panel of 10 primary virus strains
from clade B (32). Eight were originally selected for evaluating
IgG b12 and IgG 4E10, but we replaced TRJO4551.58 and
TRO.11 with REJO4541.67 and WITO4160.33 in the b12 anal-
yses because they were insensitive to all of the b12 reagents
except IgG b12. From plots of inhibitor concentration versus
percentage inhibition, we derived molar concentrations at which
50% inhibition was observed (IC50 values) for each potential
inhibitor (Table 1 and Fig. S2). We then compared various pairs
of antibody architectures by calculating the ratio of their average
molar IC50 values across all strains (Fig. 3).
All of the b12 reagents neutralized b12-sensitive virus isolates,
but the bivalent IgG and scBvFv constructs were more potent
than the monovalent scFv and Fab forms: IgG b12 was an
average of 34-fold more potent than scFv b12 (i.e., the average
molar IC50 value for the scFv divided by the average value for the
IgG was 34) and 17-fold more potent than Fab b12 (Fig. 3), and
scBvFv b12 was an average of 6.0-fold more potent than scFv b12
and 2.9-fold more potent than Fab b12 (Fig. 3). Diabody b12,
Table 1. Strain-specific IC50 neutralization values (nM) for each antibody construct
Antibody construct
b12 4E10
Virus strain scFv scBvFv diabody Fab IgG scFv scBvFv diabody Fab IgG
6535.3 760  280 41  6 1,100  200 260  80 19  3 14  3 19  3 220  90 34  8 5.0  1.3
QH0692.42 110  10 31  3 48  10 76  10 5.6  0.4 98  12 130  30 1,100  200 220  50 38  4
RHPA4259.7 12  1 7.5  1.2 19  2 11  2 1.0  0.2 100  20 320  40 680  110 760  200 250  50
SC422661.8 57  8 12  2 15  4 28  7 3.8  0.5 10  1 15  2 54  9 28  3 15  3
SF162 4.9  1.7 1.2  0.4 4.6  0.2 2.6  1.0 0.26  0.04 56  23 90  25 480  190 290  130 19  8
THRO4156.18 110  20 12  2 62  29 130  30 4.3  1.4 35  3 9.3  1.5 84  23 42  10 3.4  0.8
REJO4541.67 810  250 33  7 680  140 290  100 10  2 — — — — —
WITO4160.33 390  120 250  70 n.d. 320  60 22  3 — — — — —
TRJO4551.58 — — — — — 92  27 170  30 610  130 240  30 35  7
TRO.11 — — — — — 8.4  0.9 27  3 200  50 19  5 3.2  0.6
n.d., not done. See discussion in SI Text.
Fig. 3. Bar graph of ratios of average molar IC50 values (arithmetic means) for b12 constructs (blue) and 4E10 constructs (orange). Reagent pairs with an average
ratio of 1.0 (black line) are equal in average potencies. Ratios 1.0 indicate that reagent b is more potent than reagent a. Ratios 1.0 indicate that reagent a
is more potent than reagent b. Error bars represent the standard errors calculated from the variability in strain-specific ratios for each pair of reagents.
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however, was generally indistinguishable in neutralization potency
when compared with the monovalent construct (scFv/diabody
average IC50 ratio was 1.0 and the Fab/diabody ratio was 0.51).
The increased potencies of the IgG and scBvFv forms of b12
could result from their ability to cross-link epitopes on the
surface of the virus (i.e., avidity), their larger sizes or different
domain structures compared with the monovalent forms, or a
combination of both. None of the monovalent constructs were as
large as an IgG, so the effects of size and valency could not be
separated in comparisons involving the bivalent IgG architec-
ture. However, scBvFv b12, which contains 4 domains that are
comparable in size and structure to the 4 domains of monovalent
Fab b12, exhibited greater neutralization potency than the Fab
for all strains tested, with an average increase of 2.9-fold (Table
1 and Fig. 3). The comparison between scBvFv b12 and scFv b12
allows us to control for potential effects of domains outside the
variable regions impacting affinity and specificity in binding
because both constructs contain only VL andVH domains, yet the
bivalent scBvFv b12 showed an average 6.0-fold increase in
neutralization potency compared with scFv b12. We suggest that
the increased potencies of the bivalent IgG and scBvFv forms of
b12 relates to their abilities to cross-link epitopes on the virus,
with the larger distance between combining sites in the IgG
compared with the scBvFv permitting more cross-linking. Dia-
body b12, although bivalent and able to cross-link immobilized
gp120 in a binding assay (Figs. 1 and 2C), was equivalent to scFv
b12 in neutralization potency (Fig. 3), suggesting that the
relatively rigid pairing of 2 combining sites and shorter distance
between combining sites did not permit efficient cross-linking on
a viral surface. Comparing scBvFv b12 with the similarly sized
diabody supports the conclusion that flexibility between the
antibody combining sites is important for cross-linking epitopes
on a virus in b12-mediated neutralization as the scBvFv exhibited
a 5.7-fold average increased potency compared with the diabody.
Neutralization by 4E10 Involves only Minimal Cross-Linking of
Epitopes on a Virus.A comparison of bivalent andmonovalent 4E10
constructs shows that the 4E10 bivalent reagents exhibited only
modest improvements in neutralization potency compared with
monovalent constructs. For example, IgG 4E10 showed a 1.1-fold
and 4.4-fold improvement in potency compared with the scFv and
Fab, respectively, and the scBvFv was nearly equivalent to scFv
4E10 and only slightly more potent than Fab 4E10 (Fig. 3). These
results suggest that IgG 4E10 has a minimal ability to cross-link
epitopes on a virus and that the flexible scBvFv 4E10 generally
behaved as a monovalent reagent, as evidenced by the 0.53 scFv/
scBvFv average IC50 ratio for 4E10 versus a ratio of 6.0 for the
comparable b12 reagents. As was observed for b12, diabody 4E10
showed no increase in potency compared with the monovalent
reagents (scFv/diabody average IC50 ratio of 0.12 and Fab/diabody
average IC50 ratio of 0.48), demonstrating that neither diabody
could efficiently cross-link epitopes on the surface of a virus.
Neutralization Potencies Suggest a Size-Restricted Epitope for 4E10,
but Not b12. Comparison of IC50 ratios indicates that smaller
and/or more flexible 4E10 reagents were generally more potent
in neutralization than larger and/or less f lexible reagents, a
relationship that was not observed for the b12 reagents. For
example, scFv 4E10 was an average of 8.3-fold more potent than
the larger diabody 4E10 (average scFv/diabody IC50 ratio of
0.12), whereas the scFv b12 and diabody b12 were equally potent
(Fig. 3). In addition, scFv 4E10 was systematically more potent
than the larger Fab 4E10 (an average 4.0-fold potency increase),
contrasting with scFv b12, which was 2.0-fold less potent than
Fab b12 (Fig. 3 and Table 1). Indeed, the IgG 4E10 was the only
reagent larger than scFv 4E10 that was also more potent, but only
in 6 of the 8 strains tested (Table 1 and Table S1); for strains
RHPA4259.7 and SC422661.8 the scFv was more potent than the
IgG. By contrast, we observed no instances in which scFv b12 was
as potent as IgG b12; the smallest difference in potencies was
12-fold with an average 34-fold difference (Fig. 3 and Table S1).
These results are compatible with partial steric occlusion of the
4E10 epitope such that the larger 4E10 reagents are unable to
gain complete access. Given that Fab 4E10 was found to be an
average of 4.0-fold less potent than scFv 4E10, the occlusion
appeared to be somewhat overcome in the case of the IgG by a
modest ability to cross-link, thereby offsetting the steric penalty.
In support of the hypothesis that flexibility in a 4E10 reagent
improves access to the 4E10 epitope, we point to a comparison
between diabody 4E10 and scBvFv 4E10, both of which were
functioning as monovalent reagents during neutralization in the
majority of strains tested (Table S1): Although similar in size, the
more rigid diabody exhibited an average 4.4-fold weaker neu-
tralization potency than the scBvFv. Taken together, the com-
parison of neutralization potencies for the IgG, Fab, diabody,
and scFv forms of 4E10 and b12 suggested that the larger sizes
of the IgG, Fab, scBvFv, and diabody forms of 4E10 prevented
complete access to its epitope on gp41. See also Tables S2 and
S3 for additional information.
Discussion
In this investigation, we asked whether alternative antibody
architectures that do not naturally occur, such as a scFv, scBvFv,
or diabody, could be used to further our understanding of the
mechanisms by which the anti-gp120 antibody b12 and the
anti-gp41 antibody 4E10 neutralize primary isolates in clade B of
HIV-1. A comparative analysis of the neutralization potencies of
these architectures as well as Fab and IgG forms of these
antibodies yielded several conclusions that were consistent
across multiple strains.
First, our analysis suggested that cross-linking HIV-1 epitopes
contributes to the neutralization mechanism of IgG b12 but is
less apparent for neutralization by IgG 4E10. Inefficient cross-
linking by 4E10 may be related to its orientation when binding
gp41: Previous reports suggested that a bound 4E10 Fab is
oriented approximately perpendicular to the viral envelope (33,
34), which would require an I-shaped conformation of an IgG if
both Fabs were simultaneously engaged. By contrast, b12 Fabs
bind approximately parallel to the viral envelope (20), which
could be achieved by a T- or Y-shaped conformation. However,
although bivalency was more important for b12- than 4E10-
dependent neutralization, the avidity-dependent increase in
potency for b12 was limited relative to IgG/Fab comparisons of
antibodies that recognize antigens on other enveloped viruses
(14, 35). A potential explanation for the modest avidity-
dependent increase is that only 10% of HIV spikes lie within
the span of the 2 Fabs of an IgG (SI figure 2 in ref. 21), leaving
most spikes available for only monovalent binding.
Second, the results suggested that the 4E10 epitope on gp41
is presented in a sterically constrained environment in contrast
to the b12 epitope on gp120, which appeared to be fully
accessible to potentially neutralizing reagents. Steric occlusion of
the 4E10 epitope is consistent with the observation that a
polymeric IgM version of 4E10 was significantly less potent than
IgG 4E10 (36). The recent finding that 4E10 preferentially binds
a fusion-intermediate conformation of gp41 (37) and that neu-
tralization by IgG 4E10 is potentiated by the addition of a
peptide that holds the trimer in a prehairpin intermediate state
after attachment (38) provides additional context for interpre-
tation of the steric occlusion effect, suggesting that the scFv and
flexible scBvFv were better able to access a conformational state
of the trimeric spike compared with the IgG, Fab, or diabody
architectures. It is interesting to note, however, that occlusion
effects were less evident for 1 of the tested strains,
THRO4156.18. In this case, relative to scFv 4E10, IgG 4E10 and
scBvFv 4E10 were 10-fold and 3.9-fold more potent, respectively
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(Table S1), suggesting at least some ability for these bivalent
architectures to mediate cross-linking. THRO4156.18 is also the
only strain in which Fab 4E10 and scFv 4E10 were equally potent
(Table S1). Together, these results suggest that strain
THRO4156.18 might be suitable for vaccination efforts to raise
4E10-like antibodies.
Given the evidence for cross-linking by b12 reagents, we
considered whether cross-linking occurred within the same spike
trimer (intraspike) or between spike trimers (interspike). Anal-
ysis of a recent tomographic reconstruction of b12 Fabs bound
to trimeric HIV-1 spikes on intact virions (20) suggests that
intraspike cross-linking is not possible for IgG b12 or scBvFv b12
because the distance between 2 bound Fabs is greater than the
span of either architecture (Fig. 1 and Fig. S3). The assumption
that cross-linking is exclusively interspike allows us to address the
potential for mobility of trimeric spikes on the viral surface, an
issue that is relevant to the mechanisms of both antibody-
mediated neutralization and fusion of the HIV-1 and host cell
membranes. The low density of spikes on the surface of HIV-1
(20–23) would limit interspike cross-linking if the spikes were
immobile or slow to diffuse relative to the kinetics of antibody
binding. For both b12 and 4E10, we observed a greater avidity
enhancement for the IgG architecture over the shorter scBvFv
architecture (which span maximum distances of 15 and 11
nm, respectively; see Fig. 1), arguing in favor of a restriction to
spike mobility.
The highly conserved MPER of gp41, which contains the 4E10
epitope, has long been considered an attractive target for vaccine
design (39–47). Our observations of steric occlusion and inefficient
cross-linking by IgG 4E10 for 7 of 8 primary isolates of clade B
HIV-1 suggests that the IgG architecture is not optimal for bivalent
recognition of its epitope, providing an explanation for the modest
potency of 4E10 compared with other neutralizing antibodies (13).
Combined with the low density of surface spikes on HIV-1, these
limitations may serve as another mechanism by which HIV-1 limits
neutralization by antibodies and represent an obstacle to vaccines
that target theMPER. If so, IgG or scBvFv reagents with increased
separation and/or flexibility between combining sites might repre-
sent a previously uncharacterized class of anti-HIV-1 reagents with
increased neutralization potencies and therefore increased efficacy
against HIV-1.
Materials and Methods
Affinity Determinations by Surface Plasmon Resonance. Proteins were pro-
duced (scFvs, scBvFvs, diabodies, Fabs, IgGs) or purchased (gp120, gp41) as
described in SI Text. A Biacore 2000 biosensor system (Biacore International
AB) was used to derive affinities of the b12 and 4E10 constructs for gp120 and
gp41, respectively. In this assay, a protein (the ‘‘ligand’’) is covalently coupled
to a gold–dextran layer, and association and dissociation phases for binding
to injected protein (the ‘‘analyte’’) are measured in real time in resonance
units (RU) (48, 49). The gp120 and gp41 proteins were immobilized by random
primary amine coupling to a CM5 sensor chip as described in the Biacore
manual. Monomeric gp120 was coupled at a density of 500 RU for experiments
involving b12 constructs. gp41 was coupled at 300 RU for experiments involv-
ing scFv 4E10, scBvFv 4E10, and diabody 4E10 and at 150 RU for injections of
IgG 4E10. A mock-coupled flow cell was used as a reference blank in all
experiments. The surfaces were blocked with 3 5-min injections of 1 M
ethanolamine (pH 8.0). After blocking, regeneration solutions of 60 mM
H3PO4 (for gp120) or 10 mM NaOH (for gp41) were repeatedly injected in short
pulses until stable baselines were observed. Next, constant concentrations of
the appropriate analytes followed by regeneration solution were repeatedly
injected over both surfaces to verify reproducibility. For affinity measure-
ments, a 2-fold dilution series of each analyte was injected over the flow cells
at 100 L/min at 25 °C in 10 mM Hepes buffer (pH 7.4), 150 mM NaCl, 3 mM
EDTA, and 0.005% P-20 surfactant. Blank injections of just running buffer
were used for double referencing (50). The chip surface was regenerated
between analyte injections with 2 12-s injections.
Primary sensorgram data were preprocessed by using the Scrubber soft-
ware package (Biologic Software; www.biologic.com.au). Kinetic constants
were determined by simultaneously fitting the association and dissociation
phases of all curves (4 or 5 injected concentrations per construct) to a 1:1
binding model by using ClampXP (51). For IgG 4E10, association data were
collected at 4 concentrations, but dissociation data were collected for 2 h at
only 1 concentration and fit separately because the dissociation rate was very
slow. The 1:1 binding model describes a simple bimolecular interaction,
yielding single association (kon) and dissociation (koff) values and a macro-
scopic (apparent) equilibrium dissociation constant (KD), which includes den-
sity-dependent avidity effects that arise from the ability of bivalent constructs
(the IgG, scBvFvs, and diabodies) to cross-link immobilized antigens. Because
we wished to evaluate the effects of multivalent binding on the apparent
affinities, we did not model the data for bivalent constructs with microscopic
(stepwise) binding models because these models are defined in terms of
monovalent binding events and would yield microscopic (i.e., intrinsic) affin-
ities that do not include avidity effects. Errors for theKD values were calculated
with the formula koff/kon*[(on/kon)2  (off/koff)2]1/2, where on and off denote
the asymptotic standard errors of the rate constants calculated in ClampXP.
Molecular Weight Determinations by Static Light Scattering. Static light-
scattering experiments were performed at 25 °C by using a Superdex 75 10/30
gel filtration column (Amersham Biosciences) equipped with a Dawn Helios
light scattering photometer and an Optilab rEX refractive index detector
(Wyatt Technology). Protein samples (350 g) were injected in TBS at a flow
rate of 0.5 mL/min. Molecular weight values were calculated by using a dn/dc
value of 0.185 mL/g. All data were analyzed with ASTRA software version
5.3.1.5 (Wyatt Technology).
Analysis of Neutralization Data. In vitro neutralization assays were conducted
as described in the SI Text and previously (1, 32, 52). Molar 50% inhibitory
concentration values (IC50) were calculated by fitting the inhibition data to the
equation N  100/[1(IC50/c)H], where N is the percentage of neutralization,
c is the concentration of the reagent being tested, and H is the Hill coefficient
(KaleidaGraph v3.6, Synergy Software) (Fig. S2). For each antibody reagent,
the mean IC50 value across 8 viral strains was calculated as an arithmetic mean
by using the formula ¥ai/8; i  1, 2, …, 8, where ai refers to the IC50 value for
viral strain i (Fig. 3), and as a geometric mean by using the formula (ai)(1/8);
i 1, 2, …, 8 (Fig. S4). The ratio of the IC50 value for a reagent compared with
the IC50 value of another reagent was calculated as the ratio of the 2 means.
Our conclusions did not differ using either type of calculation.
StructureModels.Models were created by using Swiss-PDB Viewer v3.9b2 (www.
expasy.org/spdbv/) (53) and rendered in MacPymol (www.pymol.org/) (54).
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